Merck’s Keytruda fails more prostate and lung cancer PhIII trials
Merck’s cancer drug behemoth, the anti-PD1 Keytruda, has failed two more Phase III trials in the hard-to-treat prostate cancer setting and in a certain lung cancer, per a Tuesday update.
That marks more than half a dozen Phase III flops in the past 12 months for the drug, which won its first approval in 2014 and has generated dozens of billions in revenue for Merck, accounting for $20.9 billion in global sales last year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.